Merck & Co., Inc. (MRK)
| Market Cap | 190.99B |
| Revenue (ttm) | 63.92B |
| Net Income (ttm) | 17.43B |
| Shares Out | 2.51B |
| EPS (ttm) | 6.88 |
| PE Ratio | 11.06 |
| Forward PE | 8.45 |
| Dividend | $3.24 (4.26%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 15,012,309 |
| Open | 74.99 |
| Previous Close | 74.80 |
| Day's Range | 74.37 - 76.17 |
| 52-Week Range | 75.93 - 134.63 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 113.71 (+49.5%) |
| Earnings Date | Apr 24, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $113.71, which is an increase of 49.50% from the latest price.
News
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH)...
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer.
FDA Approves Merck's WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG PPGL FDA Approval News Release.
Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ET Company Participants Jannie Oosthuizen - President Peter Dannenbaum - Senior Vice President, Investor R...
US FDA expands use of Merck's cancer drug for adrenal gland tumors
The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two types adrenal gland tumors.
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
Germany's Merck drops China surcharge on orders after US-China tariff deal
German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China following the U.S.-China agreement to pause sky-high tariffs on each other, the com...
Research on Novel Treatment Approaches and Scientific Advances From Merck's Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research across more than 25 types of cancer and multiple trea...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
Trump Announces Executive Order to Lower Drug Prices
President Donald Trump says he'll sign an executive order that will lower drug prices for Americans. The order aims to align patient costs with lower prices paid abroad, focusing on Medicare and weigh...
White House release details on executive order on drug prices: Here's what to know
CNBC's Eamon Javers reports on the latest news.
European pharma stocks follow Asia peers down as Trump moves to cut prices
European drugmakers stocks fell in early trading on Monday after U.S. President Donald Trump said he would sign an executive order on reducing prescription drug and pharmaceutical prices.
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien E...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Merck Animal Health announces $895 million investment in Kansas
Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in De Soto, Kansas.
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Gover...
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bank of America 2025 Global Healthcare Conference.
Pharma imports to US surged in March as drugmakers look to avoid tariffs
Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products, which have historically been exempt from such fees.
Pharmaceutical giant details plan to create thousands of US jobs
Merck CEO Robert Davis joins 'Mornings with Maria' to discuss the new $1 billion biologics manufacturing facility slated to be built in Wilmington, Delaware, and bringing manufacturing back to the U.S...